Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells

Drug repositioning is an emerging approach to developing novel cancer treatments. Vorinostat is a histone deacetylase inhibitor approved for cancer treatment, but it could attenuate its anticancer activity by activating the mTOR pathway. The HMG‐CoA reductase inhibitor fluvastatin reportedly activat...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, Kazuki, Isono, Makoto, Miyai, Kosuke, Asano, Takako, Sato, Akinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942444/
https://www.ncbi.nlm.nih.gov/pubmed/31675763
http://dx.doi.org/10.1111/cas.14225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942444/
https://www.ncbi.nlm.nih.gov/pubmed/31675763
http://dx.doi.org/10.1111/cas.14225

Ejemplares similares